• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV 潜伏逆转剂:功能性治愈的潜在途径?

HIV latency reversal agents: A potential path for functional cure?

机构信息

São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, 14800-903, Brazil; Institute of Chemistry, São Paulo State University (UNESP), Araraquara, Brazil.

São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, 14800-903, Brazil.

出版信息

Eur J Med Chem. 2021 Mar 5;213:113213. doi: 10.1016/j.ejmech.2021.113213. Epub 2021 Jan 23.

DOI:10.1016/j.ejmech.2021.113213
PMID:33540228
Abstract

Despite the advances in Human Immunodeficiency Virus (HIV) treatment, the cure for all HIV patients still poses a major challenge, which needs to be surpassed in the coming years. Among the strategies pursuing this aim, the 'kick-and-kill' approach, which involves the reactivation and elimination of a latent HIV reservoir that resides in some CD4 T cells, appears promising. The first step of this approach requires the use of latency reversal agents (LRAs) that induce the reactivation of the latent virus. Although several classes of LRAs have been reported so far, some limitations of these compounds still need to be overcome before their clinical use. The complete exhaustion of the reservoir of latent virus will contribute to promote the second step of this approach, facilitating the elimination of the reactivated HIV. Therefore, potent, safe, and non-toxic LRAs are necessary to promote efficient elimination of the HIV-1 virus from its reservoir. In this review article, we focus on the promising LRAs that have been described in the literature over the past few years, highlighting the advantages and disadvantages of their use in the 'kick and kill' approach, thus opening a new avenue in the development of a potential cure.

摘要

尽管人类免疫缺陷病毒 (HIV) 治疗取得了进展,但治愈所有 HIV 患者仍然是一个重大挑战,这需要在未来几年内得到解决。在追求这一目标的策略中,“踢杀”方法似乎很有前途,该方法涉及潜伏 HIV 储库的再激活和消除,该储库存在于一些 CD4 T 细胞中。该方法的第一步需要使用潜伏逆转剂 (LRA) 来诱导潜伏病毒的激活。尽管迄今为止已经报道了几类 LRA,但在这些化合物用于临床之前,仍需要克服其一些局限性。潜伏病毒库的完全耗尽将有助于促进该方法的第二步,促进被激活的 HIV 的消除。因此,需要有效的、安全的、无毒的 LRA 来促进 HIV-1 病毒从其储库中有效消除。在这篇综述文章中,我们重点介绍了过去几年文献中描述的有前途的 LRA,强调了它们在“踢杀”方法中的使用的优缺点,从而为潜在治愈方法的开发开辟了新途径。

相似文献

1
HIV latency reversal agents: A potential path for functional cure?HIV 潜伏逆转剂:功能性治愈的潜在途径?
Eur J Med Chem. 2021 Mar 5;213:113213. doi: 10.1016/j.ejmech.2021.113213. Epub 2021 Jan 23.
2
Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.来自无病毒血症患者静息CD4(+) T细胞中,二苯甲酸 Ingenol 和帕比司他的体外生物活性及HIV-1潜伏逆转作用
Antimicrob Agents Chemother. 2015 Oct;59(10):5984-91. doi: 10.1128/AAC.01077-15. Epub 2015 Jul 13.
3
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.体外分析确定了有效的HIV-1潜伏逆转药物组合。
J Clin Invest. 2015 May;125(5):1901-12. doi: 10.1172/JCI80142. Epub 2015 Mar 30.
4
Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.1类选择性组蛋白去乙酰化酶(HDAC)抑制剂增强HIV潜伏逆转,同时保留最大HIV基因表达所需的HDAC亚型的活性。
J Virol. 2018 Feb 26;92(6). doi: 10.1128/JVI.02110-17. Print 2018 Mar 15.
5
Which therapeutic strategy will achieve a cure for HIV-1?哪种治疗策略能治愈 HIV-1?
Curr Opin Virol. 2016 Jun;18:14-9. doi: 10.1016/j.coviro.2016.02.001. Epub 2016 Mar 15.
6
Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.HIV-1 潜伏逆转剂联合应用中的协同作用与疗效权衡。
PLoS Comput Biol. 2018 Feb 16;14(2):e1006004. doi: 10.1371/journal.pcbi.1006004. eCollection 2018 Feb.
7
Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing.当前艾滋病病毒“踢杀”疗法研究的全景综述——有所进展,但成效不足。
BMC Infect Dis. 2017 Aug 29;17(1):595. doi: 10.1186/s12879-017-2683-3.
8
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.新的离体方法可区分体内有效和无效的逆转 HIV-1 潜伏期的单一药物。
Nat Med. 2014 Apr;20(4):425-9. doi: 10.1038/nm.3489. Epub 2014 Mar 23.
9
Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets.纳米颗粒传递 Tat 与经典潜伏期逆转剂协同作用,表达 HIV 抗原靶标。
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0020124. doi: 10.1128/aac.00201-24. Epub 2024 Jun 3.
10
A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.一种新型喹啉类 BRD4 抑制剂,针对潜伏 HIV-1 储库的另一个不同靶点,可被其他“休克”药物激活。
J Virol. 2018 Apr 27;92(10). doi: 10.1128/JVI.02056-17. Print 2018 May 15.

引用本文的文献

1
Yoda1, a Piezo1 agonist, induced latent HIV reactivation associated with upregulation of CD3/TCR complex and HLA genes.Yoda1,一种Piezo1激动剂,诱导潜伏性HIV重新激活,这与CD3/TCR复合物和HLA基因的上调有关。
Res Sq. 2025 Apr 10:rs.3.rs-6208371. doi: 10.21203/rs.3.rs-6208371/v1.
2
A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency.一项靶向CRISPR筛选确定ETS1为HIV-1潜伏的调节因子。
PLoS Pathog. 2025 Apr 8;21(4):e1012467. doi: 10.1371/journal.ppat.1012467. eCollection 2025 Apr.
3
Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation.
单宁酸通过介导CBX4降解重新激活HIV-1潜伏。
J Virol. 2025 Jan 31;99(1):e0117324. doi: 10.1128/jvi.01173-24. Epub 2024 Dec 18.
4
Pembrolizumab in an HIV-infected patient with glioblastoma.帕博利珠单抗治疗 HIV 感染合并胶质母细胞瘤患者。
Immunotherapy. 2024;16(12):803-811. doi: 10.1080/1750743X.2024.2362566. Epub 2024 Jun 18.
5
The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors.前药在增强核苷逆转录酶抑制剂性质中的应用。
Viruses. 2023 Nov 9;15(11):2234. doi: 10.3390/v15112234.
6
Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/β-catenin/TCF1 axis in CD4 T cells.通过激活 CD4 T 细胞中的 Wnt/β-catenin/TCF1 轴,抑制糖原合酶激酶-3 的药理学作用可使潜伏状态的 HIV-1 重新激活。
Emerg Microbes Infect. 2022 Dec;11(1):391-405. doi: 10.1080/22221751.2022.2026198.
7
Design and Synthesis of Hybrid Compounds as Epigenetic Modifiers.作为表观遗传修饰剂的杂化化合物的设计与合成
Pharmaceuticals (Basel). 2021 Dec 15;14(12):1308. doi: 10.3390/ph14121308.